In patients with obesity, SGLT2is might be combined with other agents having anorexigenic effects, for example, GLP‐1 receptor agonists (GLP‐1RAs) that have demonstrated favourable effects on body weight, quality of life, exercise capacity and possibly outcomes in patients with HFpEF and obesity.100, 101, 102. The gene discussed is GLP1R; the disease is obesity disorder.